Dr San Miguel speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the concept of complete response being a clear marker for predicting long term survival in myeloma.

He highlights the need for good, sensitive markers to discriminate between normal and malignant plasma cells.

He says that this could be an immunophenotypic marker based on a constellation of antigens that allow the distinction between malignant plasma cells and normal plasma cells.